Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

AC Immune SA

CIK 1651625Updated Nov 6, 2026

ACIU price & chart

Provider market data

Loading TradingView…

NASDAQ:ACIU on TradingView ↗

TradingView · Data may be delayed

About the company

AC Immune (NASDAQ: ACIU) is a clinical-stage biopharma company selectively targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases. Building on more than two decades of expertise in the field of misfolded proteins, AC Immune is advancing a diversified portfolio of disease-modifying active immunotherapies and small molecule approaches. AC Immune’s wholly-owned pipeline includes its lead program, ACI-7104, in Phase 2 development for early Parkinson's disease (PD), a progressive neurodegenerative disease affecting c.10 million people worldwide with no approved disease-modifying therapies today. By targeting misfolded alpha-synuclein, a key driver of PD progression, ACI-7104 aims to slow, or halt, the spread of the disease throughout the brain before irreversible neurological damage occurs. The Company is also advancing ACI-19764, an NLRP3 inflammasome inhibitor in Phase 1, and a preclinical intracellular small molecule alpha-synuclein program.

6-K · 2026-11-04 · 0001651625-26-000027

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 6-K filing

    6-K · 2026-11-04 · 0001651625-26-000027

  2. 3/A filing

    3/A · 2026-10-09 · 0000950103-26-015456

  3. 3 filing

    3 · 2026-10-09 · 0001651625-26-000024

  4. 6-K filing

    6-K · 2026-10-02 · 0001651625-26-000023

  5. 6-K filing

    6-K · 2026-09-23 · 0001651625-26-000020

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-09-03 · 0000950103-26-013536

  2. 6-K filing

    6-K · 2026-08-20 · 0001651625-26-000018

  3. 6-K filing

    6-K · 2026-08-11 · 0001651625-26-000016

  4. 6-K filing

    6-K · 2026-08-05 · 0001104659-26-090704

  5. 6-K filing

    6-K · 2026-06-30 · 0000950103-26-009745

Financials

FY 2025 · CHF
Revenue3,573,000CHF · FY 2025
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

Net income— · FY 2025
Assets—CHF · FY 2025
Cash— · FY 2025
Operating income-69,318,000CHF · FY 2025
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

Diluted EPS-0.7CHF/shares · FY 2025
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ4 2022Q4 2021Q3 2022Q3 2021Q2 2025Q2 2024Q2 2023Q2 2022FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossCHF——-13,516,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

-15,918,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

-21,189,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

-22,760,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

-16,833,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

-19,643,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

-70,447,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

-50,916,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-54,233,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-70,753,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCHF—————————14,800,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-14,800,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

—
AdjustmentsForIncreaseDecreaseInTradeAccountPayableCHF————————-592,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

977,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

770,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-1,073,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

AdjustmentsForSharebasedPaymentsCHF————————4,396,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

5,470,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

4,365,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

3,330,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseCHF——3,274,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

5,420,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

3,896,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

4,551,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

3,681,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

4,374,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

16,094,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

17,259,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

15,305,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

15,789,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsOperatingActivitiesCHF————————174,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

113,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

163,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

470,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

InterestReceivedClassifiedAsOperatingActivitiesCHF————————1,897,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

1,563,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

595,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

69,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCHF————————1,026,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

683,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

548,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

569,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

PaymentsToAcquireOrRedeemEntitysSharesCHF———————————0
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCHF————————15,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

——0
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2022Q4 2021Q3 2022Q3 2021Q2 2025Q2 2024Q2 2023Q2 2022FY 2025FY 2024FY 2023FY 2022
Total RevenueCHF——3,934,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

—1,306,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

687,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

——3,573,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

27,309,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

14,801,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

3,935,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

Additional Financial Items
BasicEarningsLossPerShareCHF/shares——-0.16
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

-0.22
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

-0.21
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

-0.23
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

-0.2
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

-0.23
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

-0.7
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

-0.51
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-0.64
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-0.85
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

DepreciationRightofuseAssetsCHF——142,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

141,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

260,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

169,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

134,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

141,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

1,110,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

677,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

543,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

566,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareCHF/shares——-0.16
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

-0.22
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

-0.21
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

-0.23
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

-0.2
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

-0.23
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

-0.7
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

-0.51
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-0.64
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-0.85
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesCHF————1,100,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

1,400,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

———5,500,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

4,400,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

3,300,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedCHF——212,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

231,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

188,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

170,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

189,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

173,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

690,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

752,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

793,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

750,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

FinanceCostsCHF——77,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

181,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

50,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

34,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

27,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

126,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

191,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

133,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

176,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

355,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

FinanceIncomeCHF——11,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

4,424,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

458,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

739,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

259,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

—1,865,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

3,196,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

1,044,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

69,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseCHF——3,274,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

5,420,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

3,896,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

4,551,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

3,681,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

4,374,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

16,094,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

17,259,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

15,305,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

15,789,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsCHF——4,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

———3,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

3,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

0
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

3,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

10,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

13,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesCHF——17,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

17,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

45,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

29,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

24,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

18,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

174,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

113,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

90,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

68,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

OtherOperatingIncomeExpenseCHF——262,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

255,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

28,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

41,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

317,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

207,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

94,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

142,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

1,486,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

1,343,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

PostemploymentBenefitExpenseDefinedBenefitPlansCHF————————301,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

1,794,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

2,455,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

1,751,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxCHF——-13,512,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

-15,918,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

-21,189,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

-22,760,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

-16,830,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

-19,640,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

-70,447,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

-50,913,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-54,223,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-70,740,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesCHF——-13,463,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

-20,283,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

-19,388,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

-20,961,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

-17,046,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

-19,859,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

-69,318,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

-52,378,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

-53,624,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

-70,847,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseCHF——14,385,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2022-07-01 to 2022-09-30

15,118,000
Source

6-K · 2022-10-28 · 0001104659-22-112189

2021-07-01 to 2021-09-30

16,826,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2025-04-01 to 2025-06-30

17,138,000
Source

6-K · 2025-08-05 · 0001558370-25-010174

2024-04-01 to 2024-06-30

13,682,000
Source

6-K · 2024-08-06 · 0001558370-24-010944

2023-04-01 to 2023-06-30

15,692,000
Source

6-K · 2023-08-04 · 0001558370-23-013301

2022-04-01 to 2022-06-30

56,436,000
Source

20-F · 2026-03-13 · 0001104659-26-027342

2025-01-01 to 2025-12-31

62,570,000
Source

20-F · 2025-03-13 · 0001558370-25-002855

2024-01-01 to 2024-12-31

54,606,000
Source

20-F · 2024-03-14 · 0001558370-24-003164

2023-01-01 to 2023-12-31

60,336,000
Source

20-F · 2023-03-16 · 0001558370-23-003963

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

aciu-ex99d1.htm · 6-K · 2026-11-04

Exhibit 99.1 PRESS RELEASE AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead cand…

6-K · 2026-11-04 · 0001651625-26-000027

Read attachment ↗
aciu-20260923xex99d1.htm · 6-K · 2026-09-23

Exhibit 99.1 PRESS RELEASE AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 ●All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated ●Strong immunogenicity demonstrated, with 100% response rate after three immunizations ●Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement ●Discussions with FDA regarding future development path planned for …

6-K · 2026-09-23 · 0001651625-26-000020

Read attachment ↗
aciu-20260820xex99d1.htm · 6-K · 2026-08-20

Exhibit 99.1 PRESS RELEASE AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ●ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome ●Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration ●Based on PK data the therapeutic dose is expected to be ≤10mg once daily ●To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a…

6-K · 2026-08-20 · 0001651625-26-000018

Read attachment ↗
aciu-20260811xex99d1.htm · 6-K · 2026-08-11

Exhibit 99.1 PRESS RELEASE AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) ●Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance ●Recent positive interim results showed safety and immunogenicity with early signals of activity ●Full week-100 results from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, August 11, 2026 - AC Immune SA …

6-K · 2026-08-11 · 0001651625-26-000016

Read attachment ↗
aciu-20260630xex99d1.htm · 6-K · 2026-08-05

Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2026 2025 Assets Non-current assets Property, plant and equipment 5 1,919 1,989 Right-of-use assets …

6-K · 2026-08-05 · 0001104659-26-090704

Read attachment ↗
aciu-20260630xex99d2.htm · 6-K · 2026-08-05

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the six months ended June 30, 2026, included as Exhibit 99.1 to this Report on Form 6-K. We also recommend that y…

6-K · 2026-08-05 · 0001104659-26-090704

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.